摘要
血清前列腺特异性抗原(PSA)是由PSA前体蛋白(pro PSA)经人激肽释放酶2(hk2)剪切前导肽后形成。血液中存在多种形式的PSA,包括游离PSA和结合PSA。血清pro PSA属于游离PSA中的一种,它同时存在多种亚型,其中,[-2]pro PSA(p2PSA)因不能被h K2激活而稳定存在于血液中,血清p2PSA是PSA的一种同源异构体。血清前列腺健康指数(PHI)和%p2PSA均为p2PSA的衍生指标,目前已经成为与前列腺癌(PCa)发生发展相关的分子标志物,它们能减少因血清PSA检测所致PCa过度的诊断和治疗以及提高预测PCa的准确性。本文就血清p2PSA及其衍生指标的研究进展进行综述。
Serum prostate-specific antigen（ PSA） is composed of the PSA precursor protein（ pro PSA） in the absence of the leader peptide induced by human kallikrein 2（ h K2）. There are many forms of PSA in the blood,including free PSA and bound PSA.Serum pro PSA,as a free PSA,has many isoforms,among which,[- 2]pro PSA（ p2PSA） cannot be activated by h K2 and therefore exists stably in the blood. Serum p2 PSA is a homologous isomer of PSA. Serum prostate health index and % p2 PSA,as the derivative indexes of p2 PSA and molecular markers associated with the development and progression of prostate cancer,can reduce serum PSA test-induced excessive diagnosis and treatment of the malignancy and improve the accuracy of its prediction. This review summarizes recent progress in the studies of serum p2 PSA and its derivative indexes in prostate cancer.
出处
《中华男科学杂志》
CAS
CSCD
北大核心
2015年第1期74-77,共4页
National Journal of Andrology
基金
天津市应用基础及前沿技术研究计划(12JCYBJC31400)
天津科委抗癌重大专项攻关计划项目(12ZCDZSY17200)~~
